The regulatory challenge highlighted by the NMN ruling applies to compounds with both supplement and pharmaceutical potential, such as senolytics and mitochondrial enhancers.

Every Sunday: the week’s new conflicts and verdict changes — and nothing else.

Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.